Topiramate Capsule, Extended Release
Product Images NDC 68462-371

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 68462-371). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

A cumulative rate plot showing time to first seizure for patients taking topiramate at doses of 50 mg/day and 400 mg/day over approximately 500 days. The graph compares seizure occurrence between the two dosage groups with cumulative rates on the vertical axis and time in days on the horizontal axis.*

FDA Label Image

Figure2.jpg (Figure2)

A bar chart comparing the proportion of patients (%) experiencing different levels of seizure frequency reduction from baseline, categorized by placebo and topiramate 200 mg/day treatment groups. The x-axis represents the percentage reduction in seizure frequency, and the y-axis shows the proportion of patients.*

FDA Label Image

Lbl100mg30s.jpg (Lbl100mg30s)

Packaging label for Topiramate Extended-Release Capsules 100 mg by Glenmark Pharmaceuticals Inc., USA. It specifies once-daily dosing and includes a quantity of 30 capsules. The label also provides storage instructions, a barcode, and contact information for questions. The product is prescription only.*

FDA Label Image

Lbl150mg30s.jpg (Lbl150mg30s)

Label for Topiramate Extended-Release Capsules 150 mg by Glenmark Pharmaceuticals Inc., USA. The label indicates a once-daily dosing, a package size of 30 capsules, and storage instructions. It includes a barcode and directs pharmacists to dispense the Medication Guide provided separately.*

FDA Label Image

Lbl200mg30s.jpg (Lbl200mg30s)

Topiramate Extended-Release Capsules 200 mg label from Glenmark Pharmaceuticals Inc. The label shows once-daily dosing with 30 capsules per bottle. It includes storage instructions, child safety warnings, and directs pharmacists to dispense the Medication Guide to patients. The packaging is marked Rx only and includes contact information and manufacturing details.*

FDA Label Image

Lbl25mg30.jpg (Lbl25mg30)

Topiramate Extended-Release Capsules 25 mg label with directions for use, storage conditions, and manufacturer information. The label indicates Glenmark Pharmaceuticals Inc., USA as the labeler and shows a package containing 30 capsules. It includes dosing instructions as once-daily and states the product is Rx only.*

FDA Label Image

Lbl50mg30s.jpg (Lbl50mg30s)

Topiramate Extended-Release Capsules 50 mg label from Glenmark Pharmaceuticals Inc., USA. The label states once-daily dosing, contains 30 capsules per container, and includes storage instructions and a note for pharmacists to dispense the Medication Guide separately. It features the NDC 68462-373-30 and contact information for Glenmark Pharmaceuticals.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of the active ingredient topiramate, as represented in a molecular diagram showing its specific atomic and chemical bonding arrangement.*

FDA Label Image

Company Logo

FDA Label Image

Figure3.jpg (Figure3)

A bar graph depicting the change from baseline to double-blind phase in average monthly migraine period rate for topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day compared to placebo. The chart shows results from two studies with error bars and significance indicators (* and **) for p-values, illustrating dose-related decreases in migraine period rates.*

FDA Label Image

Logo.jpg (Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.